Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The new platform introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types, according to a press release from the company.
Initially available through an early-access program for select academic, industry and company collaborators, ZetaOmics is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility. The platform combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail.
Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations.
ZetaOmics represents a significant advancement in the application of artificial intelligence to cancer research. By automating complex bioinformatics workflows, the platform has the potential to accelerate the pace of discovery and reduce the time and cost associated with traditional methods. For researchers and clinicians, this could mean faster identification of biomarkers, more efficient drug target validation, and improved reproducibility in studies—a persistent challenge in biomedical research.
The launch of ZetaOmics also signals a strategic shift for Lantern Pharma, moving beyond its core focus on rare cancers to target a broader market. With a subscription-based model, the company aims to generate new revenue streams from academic institutions, biotech and pharma companies, cancer centers, and contract research organizations. This expansion could have implications for the entire oncology research ecosystem, offering tools that democratize access to advanced computational analysis.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For more information, view the full press release at https://ibn.fm/9sIIl.
